Sino Universal Pharma (SUP) is a technology-driven pharmaceutical and health industry group, rooted in China with a global vision. Anchored by our strategic positioning as a "One-Stop Global Drug Development and Commercialization Service Provider" we are dedicated to providing high-quality finished dosages, APIs, and health products. Our differentiated solutions precisely meet the clinical medication needs of patients and medical institutions both in China and globally. Currently, headquartered in Fujian, SUP’s business footprint comprehensively covers over 30 provinces, autonomous regions, and municipalities across China, as well as the Hong Kong Special Administrative Region. Our core business is driven by two main pillars: "Global Drug Licensing in & Full-Chain Commercialization" and "In-house Drug R&D & Incubation." We have an extensive layout in key therapeutic areas, including oncology, central nervous system (CNS), digestive system, metabolism, cardiovascular and cerebrovascular diseases, anti-infection, and autoimmune diseases.Looking ahead, SUP will continue to deepen its platform-based development strategy, constantly increasing R&D investment while consolidating its commercial network advantages. Against the strategic backdrop of "Healthy China," SUP will join hands with partners, leveraging the dual power of commerce and technology to co-create a brighter and healthier future for the public!